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Iodine is a crucial component of thyroid hormones; therefore, a key requirement for thyroid hormone
biosynthesis is that iodide (I2) be actively accumulated in the thyroid follicular cell. The ability of the
thyroid epithelia to concentrate I2 is ultimately dependent on functional Na+/ I2 symporter (NIS)
expression at the plasma membrane. Underscoring the significance of NIS for thyroid physiology, loss-
of-function mutations in the NIS-coding SLC5A5 gene cause an I2 transport defect, resulting in
dyshormonogenic congenital hypothyroidism. Moreover, I2 accumulation in the thyroid cell constitutes
the cornerstone for radioiodide ablation therapy for differentiated thyroid carcinoma. However, dif-
ferentiated thyroid tumors often exhibit reduced (or even undetectable) I2 transport compared with
normal thyroid tissue, and they are diagnosed as cold nodules on thyroid scintigraphy. Paradoxically,
immunohistochemistry analysis revealed that cold thyroid nodules do not express NIS or express
normal, or even higher NIS levels compared with adjacent normal tissue, but NIS is frequently in-
tracellularly retained, suggesting the presence of posttranslational abnormalities in the transport of the
protein to the plasma membrane. Ultimately, a thorough comprehension of the mechanisms that
regulate NIS transport to the plasma membrane would have multiple implications for radioiodide
therapy, opening the possibility to identify newmolecular targets to treat radioiodide-refractory thyroid
tumors. Therefore, in this review, we discuss the current knowledge regarding posttranslational
mechanisms that regulate NIS transport to the plasmamembrane under physiological and pathological
conditions affecting the thyroid follicular cell, a topic of great interest in the thyroid cancer field.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
nd/4.0/).
Freeform/Key Words: Na+/I2 symporter, I2 deficiency disorders, I2 transport defect,
congenital hypothyroidism, differentiated thyroid cancer, radioiodine therapy
Active iodide (I2) accumulation in the thyroid follicular cell constitutes the first step in the
biosynthesis of the iodine-containing thyroid hormones [1]. Severe dietary iodine deficiency
results in impaired thyroid hormone synthesis, leading to hypothyroidism and subsequently
goiter andmental retardation in infants and children [2]. Na+/I2 symporter (NIS), an integral
plasma membrane glycoprotein located at the basolateral plasma membrane, efficiently
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mediates active I2 accumulation into the thyroid follicular cell [3]. AlthoughNISwas initially
thought to be a thyroid-specific protein, functional NIS protein expression is found in several
other tissues, such as salivary glands, stomach, small intestine, lactating mammary gland,
kidney, placenta, and ovary [4–11]. Because NIS mediates I2 transport in several tissues
other than the thyroid, it may be considered to be a master regulator of iodine metabolism.
The human NIS-coding SLC5A5 gene, located on chromosome 19p13.11, comprises 15
exons with an open reading frame of 1.929 nucleotides encoding a protein of 643 amino acids
[12]. The experimentally tested secondary structure model for NIS shows a hydrophobic
13-transmembrane segment protein with an extracellular amino terminus and a large in-
tracellular carboxyl terminus. NIS is N-glycosylated at three different asparagine residues
(N225, N489, and N502) located in the third and sixth extracellular loops, turning NIS into
a highly glycosylated plasma membrane protein [13]. In the thyroid, the electrophoretic
pattern of NIS includes a partially glycosylated (~60-kDa) and a fully glycosylated (~90- to
100-kDa) polypeptide [14]. Partially glycosylatedNIS corresponds to the polypeptide that has
not reached the medial-Golgi compartment, whereas the fully glycosylated polypeptide
corresponds to that located beyond medial-Golgi compartments (e.g., trans-Golgi network,
secretory vesicles) and at the plasmamembrane. However, in nonpolarized thyroid epithelial
cells, N-glycosylation is not critical for NIS intrinsic activity and plasma membrane ex-
pression, as demonstrated by substituting all glycosylated asparagines with glutamines
[13, 15].
NIS-mediated active I2 transport is electrogenic and relies on the driving force of the Na+
gradient generated by the Na+/K+ ATPase to simultaneously transport one I2 and two Na+
ions into the cells [16]. However, NIS also transports other anions, such as the environmental
pollutant perchlorate (ClO4
2), but with an electroneutral stoichiometry (one Na+/one ClO4
2)
[17]. Statistical thermodynamics analysis revealed that in the absence of Na+, NIS has a very
low intrinsic affinity (estimated at 200 mM) for I2; however, when two Na+ ions bind to the
transporter it significantly increases to ~20 mM. Therefore, at physiological Na+ concen-
trations, ~80% of NIS molecules are occupied by two Na+ ions, enabling them to transport
I2 highly efficiently even when the physiological I2 concentration in the bloodstream is
submicromolar [18].When the first Na+ binds to the transporter, theNIS affinity for the second
Na+ and for I2 increases significantly, indicating an allosteric interaction [18]. Scintillation
proximity assays using radioactive Na+ showed a strong cooperativity between the two Na+
binding sites, which is lost when the Na+-interacting residues S353 and T354 are replaced by
alanine [19].
The crystal structure of NIS has not yet been determined with atomic resolution. However,
Paroder-Belenitsky et al. [20] generated a rat NIS structural homology model based on the
crystal structure of the Na+/galactose symporter of Vibrio parahaemolyticus. The develop-
ment of the NIS homology model contributed to our understanding of the relationship
between the structure and function of the protein, allowing in silico simulations and
biochemical experiments to investigate the mechanism of transport. In particular, Fer-
randino et al. [21] identified residues involved in coordinating Na+ at the Na2 binding site
using molecular dynamics simulations. The simulations provided evidence for the role of
residues S66, D191, Q194, and Q263, in addition to S353 and T354 [19, 22], in coordinating
Na+ at the Na2 site. Moreover, the NIS homology model allowed the identification of a
putative I2-binding cavity equivalent in position to the galactose-binding site uncovered in
the crystal structure of theV. parahaemolyticusNa+/galactose transporter [23]. Significantly,
the Cb of nonglycine residues of different amino acid substitution at position G93 points
toward the inside of the cavity, and its side chain may interact with NIS substrates (I2 or
I2 and Na+) during the transport cycle, as reflected by significant changes in I2 affinity and
Na+/ClO4
2 transport stoichiometry in certain G93 mutants [20]. Moreover, NIS homology
model-based molecular dynamics simulation revealed several residues that may coordinate
I2 (F67, Q72, Q94, M258, and S416) and Na+ (F67, Q72, Q94, and L289) inside the putative
I2-binding cavity during the transport cycle [21]. However, additional in silico simulations
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and biochemical validation of the proposed I2 and Na+ coordinating residues are required to
provide further conclusions.
1. I2TransportDefectsCauseDyshormonogenicCongenitalHypothyroidism
Dyshormonogenic congenital hypothyroidism is caused by functional deficiency of thyroid
hormone synthesis as a consequence of loss-of-functionmutations in any of the genes involved
in the biosynthesis of thyroid hormones [24]. Very recently, mutations in the SLC26A7 gene
were associated with thyroid dyshormonogenesis [25, 26]. Patients with abnormal SLC26A7
function showed preserved I2 accumulation but reduced I2 organification [25]; however, the
role of SLC26A7 in intrathyroidal I2 metabolism physiology remains uncertain. Signifi-
cantly, mutations in the SLC5A5 gene cause an uncommon autosomal recessive condition
known as I2 transport defect (ITD), a consequence of impaired I2 accumulation in the thyroid
follicular cell [27]. An ITD is suspected when clinical or biochemical hypothyroidism is di-
agnosed in the presence of reduced to absent I2 accumulation in a eutopic thyroid gland, a
reduced saliva-to-plasma I2 ratio, and normal to high serum thyroglobulin levels [28]. To
date, 16 different loss-of-function SLC5A5 gene mutants (-54C.T, V59E, G93R, R124H,
Q267E, V270E, C272X, Y324LfsX12, Y348D, T354P, G395R, S509RfsX6, G543E,
M143_Q323del, V287_G288del, and A439_P443del) have been identified in the homozygous or
compound heterozygous state in patients with an ITD [27, 29]. However, genetic defects in
other genes potentially required for functional NIS expression in thyrocytes have not been
reported to cause ITDs. To date, the only protein known to facilitate efficient NIS-mediated I2
transport in thyroid cells is the constitutively active K+ channel KCNQ1–KCNE2. Signifi-
cantly, KCNE2 knockout mice developed hypothyroidism owing to decreased NIS-mediated I2
accumulation, but not abnormal NIS expression at the plasma membrane, in the thyroid
follicular cell [30, 31].
Detailed evaluation of patients with different loss-of-function SLC5A5 mutations has
demonstrated a substantial clinical heterogeneity that seems to correlate with residual
mutant NIS activity [32]. The resulting raise in TSH levels after a reduction in thyroid
hormone synthesis may overcome a partial defect in mutant NIS activity by enhancing NIS
expression, as demonstrated in patients carrying themissensemutant T354PNIS [33, 34]. In
sharp contrast, patients harboring homozygous fully inactive NIS mutants developed hy-
pothyroidism with significant clinical manifestations as a neonate [32]. Additionally, a
marked clinical heterogeneity has been reported in patients harboring the same NIS mutant
[33, 34]. The levels of dietary I2 intake significantly influence thyroid function in patients
with an ITD, especially in those whose mutant NIS protein retains residual activity. Sig-
nificantly, marked differences in hypothyroidism onset were noticed between siblings fed
during infancy with breast milk produced by a lactating mother under high dietary I2 intake
or regular artificial milk that contains lower levels of I2 [33]. Consistent with these findings,
Ferrandino et al. [35] recently developed an NIS knockout mouse model that recapitulated
the conditions of ITDs and provided evidence that high dietary concentrations of I2 make it
possible for I2 to enter the thyroid follicular cells—even in the absence of functional NIS
expression—through low-affinity mechanisms, thus facilitating partial thyroid hormone
biosynthesis. On a different note, Mizokami et al. [36] demonstrated the importance of
prophylactic iodine supplementation in healthy breast-fed newborns whose lactating
mothers carry mutations in the SLC5A5 gene, as NIS mediates I2 accumulation in breast
milk, to prevent the development of hypothyroidism in the nursing newborn due to I2-deficient
breast milk.
A thorough molecular characterization of several ITD-causing NIS mutants has provided
significant insights into the mechanisms operating during the transport cycle and ion co-
ordination [20, 22], the identification of specific residues or regions required for proper folding
of the protein [15, 37, 38], and specific regions important for NIS transport to the plasma
membrane, but not for its intrinsic activity, and potentially involved in the interaction with
adaptor proteins (APs) required in the intracellular transport process [37, 39]. In particular,
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themissensemutant R124HNIS does notmediate I2 accumulation in whole cells because the
mutant protein is fully retained in the endoplasmic reticulum. Amino acid substitutions at
position 124, located in the intracellular loop 2, revealed a key structural role for the d-amino
group of R124 or Q124 in NIS targeting to the plasma membrane. Indeed, an intramolecular
interaction between the d-amino group of R124 and the thiol group of C440, located in the
intracellular loop 6, is essential for proper folding required for NIS sorting out through an
endoplasmic reticulumquality-control system [37].Moreover, V270ENISmediatesmarkedly
reduced I2 uptake inwhole cells because the transport of the protein to the plasmamembrane
is severely impaired. A negatively charged residue at position 270, located at the intracellular
end of transmembrane segment 7, produces a profound change in the electrostatic potential
surface of a positive patch in the intracellularly facing domain of themutant NIS protein that
may mask an uncharacterized sorting motif recognized by APs key for NIS transport to the
plasma membrane [39].
2. Regulation of NIS Transport to the Plasma Membrane
NIS expression at the plasmamembrane in the thyroid follicular cell is not only important for
I2 accumulation required for thyroid hormone biosynthesis, but also constitutes the cor-
nerstone for radioiodide therapy for hyperthyroidism and differentiated thyroid carcinoma
[40, 41]. Despite the physiological and clinical relevance of NIS plasma membrane ex-
pression, little is known regarding the molecular mechanisms underlying NIS transport to
the plasmamembrane, a pursuit that could lead to new therapeutic interventions to increase
the effectiveness of radioiodide therapy.
TSH constitutes the primary regulator of NIS expression in the thyroid follicular cell by not
only stimulating NIS expression at the transcriptional level, but it is also required at
posttranslational levels for targeting NIS to, and/or retaining it at, the plasmamembrane. In
FRTL-5 rat thyroid cells, immunofluorescence analysis demonstrated that after TSH
withdrawal, NIS molecules located in the plasma membrane are redistributed to unchar-
acterized intracellular compartments [42]. Indeed, I2 uptake was evidenced in sealed
membrane vesicles prepared from FRTL-5 cells that have lost the ability to accumulate I2
due to TSH deprivation, suggesting that those intracellularly retained NIS molecules are
fully active [43]. Moreover, in FRTL-5 cells, TSH modulates the phosphorylation pattern of
the NIS carboxyl terminus, which mainly occurs on serine residues [42]. Bioinformatics
analyses predict that the NIS carboxyl terminus contains several phosphorylation consensus
sequence motifs for protein kinases, including glycogen synthase kinase 3, protein kinase A,
and protein kinase C. In particular, considering that phosphorylation has been reported to
play a role in regulating the transport to the plasma membrane of different channels and
transporters, as well as the activation of several protein kinases as mediators of TSH actions
in thyroid cells, it is possible to speculate that phosphorylation might constitute a post-
translational modification involved in the NIS intracellular transport process. Significantly,
Vadysirisack et al. [44] identified different intracellularly located, functionally relevant NIS
phosphorylated residues by mass spectrometry in HEK-293 heterologously expressing rat
NIS. Although biochemical data suggested that the phosphorylation status of S43 and S581
modulates the activity of the protein, whereas that of T577maymodulate its stability, none of
the identified phosphorylated residues affects NIS transport to the plasmamembrane. Thus,
the molecular mechanism regulating TSH-stimulated NIS transport to, retention at, and
removal from the plasma membrane remains unknown.
Regarding structural determinants that control NIS transport to the plasma membrane,
new avenues were opened after the functional characterization of the ITD-causing
NIS truncated and frame-shifted mutant S509RfsX6—reported in the literature as S515X
NIS—missing transmembrane segment 13 and the carboxyl terminus of the protein.
S509RfsX6 NIS is fully intracellularly retained [45], thus suggesting that the carboxyl
terminus may contain crucial information for proper NIS transport to the plasmamembrane.
Recently, based on the NIS homology model, we reported that the intracellularly facing
doi: 10.1210/js.2018-00100 | Journal of the Endocrine Society | 225
humanNIS carboxyl terminus comprises residues I546 to L643, and we provided biochemical
evidence showing that the deletion of the carboxyl terminus rendered the mutant I546* NIS
retained in the endoplasmic reticulum [46]. Moreover, given the role of the carboxyl terminus
in NIS transport to the plasma membrane, we generated several NIS mutants missing
internal regions of the carboxyl terminus, and its biochemical characterization revealed that
the carboxyl terminus segment between residues I546 and K618, containing a putative
tryptophan-acidic motif (W565D566), is required for NIS exit from the endoplasmic reticulum
and subsequent transport to the plasma membrane in nonpolarized epithelial cells [46, 47].
Although the molecular mechanisms underlying NIS export from the endoplasmic reticulum
in thyroid cells remain elusive, our experimental evidence supports that the carboxyl ter-
minus contains crucial information for functional NIS plasma membrane expression [46].
Although heterologous rat NIS expression in the epithelial cell line MDCK—a cell model
that recapitulates a polarized epithelial monolayer and preserves the native polarity of
several heterologously expressed thyroid proteins [48, 49]—is largely targeted to the
basolateral plasmamembrane, Dohan et al. [17] developed a rat NIS mutant missing the last
43 amino acids (T575* NIS) that exhibited equivalent I2 transport properties to wild-type rat
NIS, but when heterologously expressed into polarizedMDCK cells, it is targeted to the apical
plasma membrane. Although T575* NIS was developed to study NIS-mediated polarized
ClO4
2 transport, these findings indirectly suggest that the region comprised between amino
acids T575 (the residue equivalent to V580 in human NIS) and L618 in the rat NIS sequence
(the rat ortholog has 618 amino acids) carries essential determinants for basolateral sorting.
Therefore, considering that the segment between amino acids V580 and K618 (the segment
between amino acids K618 and Q639 is dispensable for NIS basolateral expression) would be
critical for human NIS basolateral sorting, we focused our studies on elucidating the role of
these amino acids. Significantly, we uncovered a highly conserved basolateral sorting motif
consisting of an acidic cluster followed by a single leucine (EExxxL) between amino acids 578
and 583 of human NIS [46]. Disruption of the carboxyl-terminal monoleucine-based sorting
motif causes human and rat NIS to be missorted to the apical plasmamembrane in polarized
MDCK cells, indicating that this sorting motif, which is highly conserved across species,
constitutes a sorting signal exclusively required for basolateral NIS expression. Interest-
ingly, similar observations were evidenced in polarized FRT rat thyroid cells that, although
do not express NIS endogenously, constitute the only thyroid follicular cell line that forms
polarized epithelial monolayers [46].
Leucine-based sorting motifs are frequently recognized by heterotetrameric clathrin AP
complexes that link clathrin to the cargo in clathrin-coated vesicles that carry proteins to
different destinations within the cell; in particular, the AP-1A and AP-1B hemicomplex g-s1
recognizes basolateral [D/E]xxxL[L/I] leucine–based sorting motifs. Therefore, considering
that AP-1B expression is epithelial cell specific and differs from the ubiquitous AP-1A by the
medium subunitm1B, our studies in polarizedm1B knocked-downMDCK cells heterologously
expressing human NIS demonstrated that the AP-1B complex is required for NIS sorting
exclusively to the basolateral plasmamembrane [46].Moreover, computer simulations support a
direct recognition of the monoleucine-based basolateral sorting motif by the AP-1 g-s1
hemicomplex [46]. Taken together, our results strongly suggest that AP-1B participates in
the recognition of the carboxyl terminus–located monoleucine-based motif, thus sorting NIS
to the basolateral plasma membrane.
Bioinformatics assessing the amino acid sequence encoding the NIS carboxyl terminus
revealed the presence of several conserved sorting motifs that, in other plasma membrane
proteins, are involved in their transport to the plasma membrane [50]. In particular, NIS
contains a putative class I PDZ-binding motif [S/T]-X-FCOOH located at the carboxyl-terminal
edge of the protein. PDZ-binding motifs are recognized by PDZ domain–containing proteins
that by working as scaffold or APs participate at various levels in membrane protein
transport and sorting to the plasmamembrane [51]. However, it seems unlikely that the PDZ-
bindingmotif is the determinant for NIS expression at the plasmamembrane, as the addition
of an epitope tag at the carboxyl terminus that masks the carboxylate group required for the
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recognition of the PDZ motif does not impair NIS expression at the plasma membrane [52,
53]. Significantly, the recognition of the PDZ-binding motif of NIS by the PDZ domain–
containing leukemia-associated RhoA guanine exchange factor promotes cell invasion and
migration in intracellularly NIS-expressing cancer cells [54, 55].
Recently, Darrouzet et al. [50] reported the first systematic evaluation of potential NIS
intracellularly located sorting motifs presumably involved in the transport of the protein to
the plasma membrane. The authors identified an internal noncanonical PDZ-binding motif
comprising residues 118 to 121, located in the intracellular loop 2, which plays a crucial role in
NIS transport to the plasma membrane. The substitution L121A disrupted the mentioned
PDZ-binding motif leading to complete retention of the mutant NIS protein in the endo-
plasmic reticulum, as revealed by its electrophoretic pattern on immunoblot analysis [50].
However, a remaining open question is to determine whether the mutant L121A prevents
proper folding of the protein and then the quality control system retains it in the endoplasmic
reticulum or, alternatively, the recognition of this PDZ-binding motif is required to export
NIS from the endoplasmic reticulum.
3. The Molecular Basis for Radioiodide Therapy of Differentiated
Thyroid Carcinoma
For .75 years, the ability of thyroid cells to accumulate I2 has constituted the molecular
basis for the diagnosis and treatment of differentiated thyroid carcinoma [56]. Radioiodide
therapy used to ablate thyroid cancermetastases and remnants after thyroidectomy has been
the most successful targeted internal radiation therapy ever designed. Retrospective studies
have demonstrated that the ability of tumor cells to accumulate I2 is the best indicator of
disease-free survival [57–59]. Currently, TSH-stimulated radioiodide adjuvant therapy is
routinely recommended after total thyroidectomy for high-risk differentiated thyroid car-
cinomas [60]. However, differentiated thyroid tumors often exhibit reduced (or even un-
detectable) I2 transport compared with normal thyroid tissue, and they are diagnosed as cold
nodules on thyroid scintigraphy. Despite this reduction, .70% of differentiated thyroid
carcinomas accumulate I2 to some extent, which is still sufficient to achieve appropriate
radioiodide accumulation for treatment [61]. Unfortunately, 30% to 50% of metastases from
differentiated thyroid tumors completely lose their ability to accumulate I2, causing them to
become refractory to radioiodide therapy [62]. Therefore, in these cases, other therapeutic
alternatives should be considered [63]. Loss of I2 accumulation is associated with poor
prognosis; patients with thyroid cancer metastases that accumulate I2 showed a survival
rate at 10 years of ~56%, whereas survival is drastically reduced to ;10% in patients with
radioiodide refractory metastases [58].
Radioiodide therapy effectivity is ultimately dependent on functional NIS expression at
the plasmamembrane of tumor cells, as deficient radioiodide accumulation is themajor cause
of treatment failure [62]. However, NIS gene expression is frequently downregulated in
thyroid cancer. The Cancer Genome Atlas study of nearly 500 papillary thyroid carcinomas,
the most common form of differentiated thyroid cancer, revealed that NIS gene expression is
lower than in normal thyroid tissue [64]. Moreover, the study demonstrated that NIS gene
expression is significantly higher in carcinomas showing a RAS-like phenotype, having
relatively higher thyroid differentiation scores than in those with a BRAF-like phenotype
[64]. Indeed, NIS gene expression is totally silenced in poorly differentiated and anaplastic
thyroid carcinomas [65]. Although several transcriptional and posttranscriptional mecha-
nisms have been postulated to explain a repression of NIS gene expression in thyroid tumors,
because of the thrust of this review, these mechanisms are not reviewed [66, 67]. Para-
doxically, several immunohistochemical analyses (using different antihuman NIS anti-
bodies) showed that NIS is frequently expressed at different levels in differentiated thyroid
carcinomas compared with adjacent normal tissue. Recently, Tavares et al. [68] reported a
comprehensive bibliographic revision of different studies assessing NIS protein expression
by immunohistochemistry in thyroid carcinomas. Surprisingly, NIS expression was mainly
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located in intracellular compartments, suggesting the presence of plasmamembrane transport
abnormalities [68–75]. Significantly, Peyrottes et al. [76] have questioned that the real sig-
nificance ofNIS intracellular staining is due tononspecific binding of the antibodies, a topic that
remains to be clarified. Interestingly, intracellular NIS retention in differentiated thyroid
carcinomas has been pointed out as a reason for the decreased radioiodide accumulation in
tumor cells, as impaired NIS transport to the plasma membrane would hamper its activity.
Significantly, NIS mutations have not been identified in thyroid tumors [77], so it cannot be
structural defects that retain NIS intracellularly in these tumors, which stands in contrast to
the situation in some patients with an ITD [15, 37]. Therefore, the paradoxical observations of
reduced I2 uptake and intracellularly retained NIS protein expression highlight the impor-
tance of elucidating the posttranslational mechanisms that regulate NIS expression at the
plasma membrane under physiological and pathological conditions.
Considering the high prevalence of BRAFV600E-positive radioiodide-refractory metastatic
papillary carcinomas, Riesco-Eizaguirre et al. [78] investigated NIS expression by immu-
nohistochemistry in a cohort of 60 papillary carcinomas, and they reported a significant
reduction of NIS expression and impaired transport to the plasma membrane in tumors
harboring the oncogene BRAFV600E. Furthermore, in vitro experiments demonstrated that
ectopic BRAFV600E expression in PCCl3 thyroid cells induces a sharp redistribution of NIS
expression from the plasma membrane to uncharacterized intracellular compartments, thus
reducing I2 accumulation, followed by a gradual decrease in NIS transcriptional expression
involving TSH-independent processes. Mechanistically, the oncogenic transformation in-
duced by BRAFV600E might either repress APs involved in NIS transport to the plasma
membrane or, alternatively, induce the expression of APs that remove NIS from the cell
surface, thus leading to its intracellular retention.
To date, the pituitary tumor–transforming gene–binding factor (PBF) has been charac-
terized as the only NIS-interacting protein that may be involved in defective NIS plasma
membrane expression in thyroid cancer. Smith et al. [79] reported that ectopic PBF over-
expression posttranslationally represses I2 uptake by binding to NIS and leading to its in-
ternalization into clathrin-coated CD63-positive late endosomes.Moreover, the proto-oncogene
tyrosine kinase Src-mediated PBF phosphorylation at tyrosine 174 is required for its physical
interactionwithNIS. Significantly, abrogation of Src kinase activity restoresNIS expression at
the plasma membrane and I2 accumulation in human thyroid cancer cells [80].
Recently, Amit et al. [81] provided evidence of a reduced expression of phosphatidylinositol
glycan anchor biosynthesis class U (PIGU), a subunit of membrane-bound glycosylphosphati-
dylinositol (GPI) transamidase complex that catalyzes the addition of a GPI anchor to
substrate proteins in the endoplasmic reticulum, in papillary thyroid carcinoma. Sig-
nificantly, PIGU overexpression restored NIS expression at the plasma membrane and I2
accumulation, allowing radioiodide therapy, in the human well-differentiated thyroid
carcinoma cell line K1 carrying the oncogene BRAFV600E [81]. Although functional PIGU
expression appears to participate in a posttranslational mechanism necessary for NIS
transport to the plasma membrane, the absence of a consensus sequence for GPI anchoring
rules out that NIS is a GPI-anchored protein. Thus, a defect in the GPI transamidase complex
might cause either a deficient transport of membrane proteins to the plasma membrane,
whose sorting into specific secretory vesicles depends on GPI-anchored proteins, or a defi-
ciency in a key, still unidentifiedGPI-anchored protein necessary for properNIS transport to the
plasma membrane.
Recent progress in understanding the molecular mechanisms that repress functional NIS
expression has brought about possibilities of new therapeutic approaches, which may de-
crease the dose of radioiodide as well as expand the application of radioiodide therapy to
radioiodide-refractory thyroid cancers. Indeed, emerging therapies, still in the clinical phase
of study, using small-molecule inhibitors (i.e., dabrafenib and selumetinib) have shown
promising effects enhancing radioiodide accumulation in radioiodide-refractory differentiated
thyroid cancer metastasis [82, 83]. Although single-agent therapy has shown poor long-term
responses, dabrafenib and selumetinib treatment overcome radioiodide resistance, thus
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allowing subsequent radioiodide ablation protocols. Future phase 3 studies evaluating the
clinical benefit from the combination of dabrafenib or selumetinib and radioiodide therapy
in larger cohorts of patients and, perhaps, in particular subgroups of patients according to the
oncogenic driver event are eagerly awaited. Moreover, the identification of novel small-
molecule inhibitors exhibiting stronger and sustained inhibition of MAPK/ERK signaling
may provide novel strategies to enhance radioiodide accumulation in radioiodide-refractory
differentiated thyroid cancer metastasis [84].
4. Perspectives and Future Directions
Radioiodide accumulation in the thyroid tissue has been exploited in clinical medicine to
diagnose, treat, and follow up thyroid pathologies for several decades before the mechanism
mediating I– accumulation was characterized at themolecular level. Since the cloning of NIS,
substantial progress has been made in understanding not only the mechanisms underlying
ion coordination during the transport cycle, its transport to the plasma membrane, and its
transcriptional repression in thyroid cancer, but also broadening NIS application to imaging
and therapeutic procedures for various nonthyroid diseases [85, 86]. Although we have
learned much about NIS, in the sections below, we pose major questions that remain to
be investigated.
A. What Are the Mechanisms Underlying NIS Basolateral or Apical Plasma Membrane
Sorting in Different Tissues Under Physiological Conditions?
Considering different tissue-specific I– handling requirements (i.e., absorption, accumula-
tion, or secretion), NIS expression in different tissues also displays different basolateral-to-
apical localization patterns. The analysis of NIS cDNA nucleotide sequence in different
tissues (i.e., thyroid, salivary gland, lactating mammary gland, and stomach) yielded full
identity [87]. Therefore, factors other than the NIS sequence, such as posttranslational
modifications or differential tissue expression of specific APs that decode common sorting
signals located in the NIS carboxyl terminus, may regulate NIS polarized transport to the
plasma membrane. In agreement, Schreiner et al. [88] showed that the absence of the
epithelial-specific basolateral clathrin-adaptor AP-1B in renal proximal tubule epithelial
cells determines that many cognate basolateral plasma membrane proteins are expressed in
the apical membrane, thus optimizing the reabsorption of nutrients in the kidney. Currently,
our knowledge regarding sortingmotifs and APs involved inNIS export from the endoplasmic
reticulum, polarized transport to the plasma membrane, and retention at the plasma
membrane in the thyroid follicular cells remains partially understood, and in other tissues
uncertain.
B. What Are the Mechanisms Underlying NIS Intracellular Retention in Thyroid Cancer?
The efficacy of radioiodide therapy is directly related to the therapeutic dose of radiation
delivered to tumor cells, which is ultimately dependent on functional NIS expression at the
plasma membrane [62]. From a therapeutic perspective, improving NIS-mediated radio-
iodide therapy for thyroid cancer is a priority for developing strategies aimed at enhancing
NIS plasma membrane expression, not only to stimulate NIS transcription, as NIS defective
transport to the cell surface may cause radioiodide treatment failure. Importantly, thera-
peutic interventions allowing more NIS molecules to reach the plasma membrane of tumor
cells would dramatically improve radioiodide therapy efficacy and lead to the use of lower
radioiodide doses, thus minimizing side effects, or to the use of radioiodide as an adjuvant
with kinase inhibitors targeting oncogene activity or oncogene-activated signaling pathways
to recover NIS transcriptional expression.
Recently, Amit et al. [81] demonstrated that functional PIGU expression in K1 cells is
transcriptionally repressed in response to BRAFV600E-triggered MAPK/ERK signaling, as
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chemical inhibition of MEK/ERK signaling restores PIGU protein expression. Direct bio-
chemical evidence indicating that inhibition of MEK/ERK signaling restores I– accumulation
in thyroid cancer cell lines relies on functional PIGU expression has not been established.
However, these data uncover a novel posttranslational mechanism involved in radioiodide
resistance, whose better understanding may lead to develop novel strategies to restore
radioiodide accumulation in thyroid cancer cells.
5. Search Strategies
We searched MEDLINE for English language articles and references of relevant articles
published between 1996 and 2018 using the search terms “Na+/I– symporter or sodium iodide
symporter,” “congenital hypothyroidism,” “iodide transport defect,” “basolateral or apical
sorting in epithelial cells,” “thyroid cancer,” “radioiodine therapy”, and “radioiodine-refractory
thyroid cancer.”
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